CR Pharma’s Subsidiary CR Double-Crane Issues RMB1.00 Billion Three-Year Bonds at 1.65% Coupon

Bulletin Express

03/26

China Resources Pharmaceutical Group Limited (CR Pharma) announced that its 59.95%-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), has completed the public issuance of the first tranche of 2026 corporate bonds to qualified investors in mainland China.

The offering raised up to RMB1.00 billion with a three-year maturity and carries an annual coupon rate of 1.65%. Net proceeds will be applied to repay interest-bearing debt and to supplement working capital, in line with the filing approved by the China Securities Regulatory Commission.

The transaction complies with Rule 13.09 of the Hong Kong Listing Rules and the Inside Information Provisions of the Securities and Futures Ordinance. CR Pharma advises shareholders and potential investors to exercise caution when dealing in its securities.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1129458795"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1129458795\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1129458795?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 19:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129458795","market":"hk","top_or_hot":-1,"title":"CR Pharma’s Subsidiary CR Double-Crane Issues RMB1.00 Billion Three-Year Bonds at 1.65% Coupon","media":"Bulletin Express","content":"<p>China Resources Pharmaceutical Group Limited (CR Pharma) announced that its 59.95%-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), has completed the public issuance of the first tranche of 2026 corporate bonds to qualified investors in mainland China.</p>\n<p>The offering raised up to RMB1.00 billion with a three-year maturity and carries an annual coupon rate of 1.65%. Net proceeds will be applied to repay interest-bearing debt and to supplement working capital, in line with the filing approved by the China Securities Regulatory Commission.</p>\n<p>The transaction complies with Rule 13.09 of the Hong Kong Listing Rules and the Inside Information Provisions of the Securities and Futures Ordinance. CR Pharma advises shareholders and potential investors to exercise caution when dealing in its securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CR Pharma’s Subsidiary CR Double-Crane Issues RMB1.00 Billion Three-Year Bonds at 1.65% Coupon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCR Pharma’s Subsidiary CR Double-Crane Issues RMB1.00 Billion Three-Year Bonds at 1.65% Coupon\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-26 19:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Resources Pharmaceutical Group Limited (CR Pharma) announced that its 59.95%-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), has completed the public issuance of the first tranche of 2026 corporate bonds to qualified investors in mainland China.</p>\n<p>The offering raised up to RMB1.00 billion with a three-year maturity and carries an annual coupon rate of 1.65%. Net proceeds will be applied to repay interest-bearing debt and to supplement working capital, in line with the filing approved by the China Securities Regulatory Commission.</p>\n<p>The transaction complies with Rule 13.09 of the Hong Kong Listing Rules and the Inside Information Provisions of the Securities and Futures Ordinance. CR Pharma advises shareholders and potential investors to exercise caution when dealing in its securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"华润医药","start_time":0,"source_url":"","article_id":"1129458795","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129458795","pubTimestamp":1774523095,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China Resources Pharmaceutical Group Limited (CR Pharma) announced that its 59.95%-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), has completed the public...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药"},"translate_title":"华润医药子公司华润双鹤发行人民币10亿元三年期债券，票面利率为1.65%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"China Resources Pharmaceutical Group Limited (CR Pharma) announced that its 59.95%-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), has completed the public issuance of the first tranche of 2026 corporate bonds to qualified investors in mainland China.\nThe offering raised up to RMB1.00 billion with a three-year maturity and carries an annual coupon rate of 1.65%. Net proceeds will be applied to repay interest-bearing debt and to supplement working capital, in line with the filing approved by the China Securities Regulatory Commission.\nThe transaction complies with Rule 13.09 of the Hong Kong Listing Rules and the Inside Information Provisions of the Securities and Futures Ordinance. CR Pharma advises shareholders and potential investors to exercise caution when dealing in its securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}